Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Foghorn Therapeutics ( (FHTX) ) has provided an update.
On February 23, 2026, Foghorn Therapeutics appointed veteran finance executive Ryan D. Maynard as chief financial officer, with immediate effect, replacing interim CFO Jeff Sacher. Maynard assumes the roles of principal financial and accounting officer under an employment agreement that includes a $510,000 base salary, performance-based bonus eligibility, a $90,000 signing bonus, and stock options for 400,000 shares vesting over four years.
Maynard brings more than 25 years of experience leading financial strategy and capital markets activities at public and private biopharmaceutical and healthcare companies, including prior CFO roles at Cara Therapeutics, LetsGetChecked, Blade Therapeutics, and Rigel Pharmaceuticals. His background in raising over $1 billion, executing strategic transactions, and supporting drug approvals and launches is expected to strengthen Foghorn’s financial leadership as it advances its oncology pipeline and partnership programs.
The most recent analyst rating on (FHTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses, negative equity, and negative cash flows). Technicals are moderately positive with price above key moving averages and a positive MACD, while valuation remains challenged due to loss-making status and no dividend. Recent corporate events are a clear positive, notably the premium-priced $50M financing that extends runway.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing a novel class of oncology medicines that target genetically determined dependencies within the chromatin regulatory system. Using its proprietary Gene Traffic Control platform, the company systematically identifies and validates drug targets to advance multiple product candidates for the treatment of serious cancers.
Average Trading Volume: 170,132
Technical Sentiment Signal: Buy
Current Market Cap: $331.6M
For detailed information about FHTX stock, go to TipRanks’ Stock Analysis page.